IGLV3-21R110 and ibrutinib treatment: Results from the double-blind, randomized, placebo-controlled GCLLSG CLL12 trial in early-stage CLL.

guest :: login DKFZ
		Search		Submit		Personalize Your alerts Your baskets Your searches		Help

Home > Publications database > IGLV3-21R110 and ibrutinib treatment: Results from the double-blind, randomized, placebo-controlled GCLLSG CLL12 trial in early-stage CLL. > Access to Fulltext

Information
Files

IGLV3-21R110 and ibrutinib treatment: Results from the double-blind, randomized, placebo-controlled GCLLSG CLL12 trial in early-stage CLL. - DKFZ-2026-01461

Main document file(s):

Similar records

DKFZ :: :: :: ::
Powered by v1.1.7 |
Maintained by

Impressum | Data Privacy Policy